{
  "url": "https://struct.news/briefs/jazzs-86-point-margin-swing-comes-with-a-bigger-pipeline-bill",
  "title": "Jazz’s 86-Point Margin Swing Comes With a Bigger Pipeline Bill",
  "summary": "R&D reached $207.5 million in the three months ended June 30 even as operating margin climbed to 20.5%.",
  "published_at": "2026-08-03T20:19:58.938581+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Jazz Pharmaceuticals plc",
    "ticker": "JAZZ",
    "cik": "1232524",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-03",
    "accession": "0001232524-26-000045",
    "url": "https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-06",
    "url": "https://www.sec.gov/Archives/edgar/data/1232524/000123252425000063/jazz-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 4267586000,
      "display": "$4.3B",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001232524-26-000045",
        "filing_date": "2026-08-03"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 4.881750820236186,
      "display": "+4.9%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001232524-26-000045",
        "filing_date": "2026-08-03"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -10.081577735047402,
      "display": "-10.1%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001232524-26-000045",
        "filing_date": "2026-08-03"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "R&D costs increased as clinical studies and outside services for zanidatamab rose, with Jazz expecting further R&D growth.",
      "importance": "medium",
      "evidence": "R&D expenses increased by $17.6 million in the three months ended June 30, 2026, compared to the same period in 2025, driven by an increase in clinical studies and outside services costs, primarily due to higher costs related to zanidatamab.",
      "source_date": "2026-08-03"
    },
    {
      "type": "demand",
      "statement": "Zepzelca sales growth is tied to increased volume and adoption in first-line maintenance ES-SCLC, partly offset by lower second-line use.",
      "importance": "medium",
      "evidence": "Zepzelca product sales increased in the three and six months ended June 30, 2026, compared to the same periods in 2025, primarily due to increased sales volumes, reflecting continued adoption in the first-line maintenance ES-SCLC setting",
      "source_date": "2026-08-03"
    }
  ],
  "related_tickers": [
    "JAZZ"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}